Predicting and treating recurrence in intermediate-risk prostate cancer patients remains a
challenge despite having identified genomic instability and hypoxia [,] as risk factors. This …

Recent studies show that prostate cancer cells are able to survive in a hypoxic tumor
environment, and the extent of tumor hypoxia correlates with poor clinical outcome …

Despite recent advances, the efficacy of androgen/androgen receptor (AR)-targeted therapy
remains limited for many patients with metastatic prostate cancer. This is in part because …

BACKGROUND Androgen withdrawal, the standard therapeutic strategy for advanced
prostate cancer, induces a rapid reduction of blood flow to prostate and prostate cancer …

Hypoxia confers resistance to common cancer therapies, however, it has also has been
shown to result in genetic alterations which may allow a survival advantage and increase …

The metabolic organization of both normal and malignant prostate cellular phenotypes
involves some unusual and surprising features. In particular, both conditions exhibit ratios of …

Prostate cancer is the second most common cancer diagnosed in men and the fifth-leading
cause of cancer death in men worldwide. Like any solid tumor, the hypoxic …

Increasingly, the tumor microenvironment and hypoxia are being studied as potential
prognostic factors in prostate cancer given their effects on the hypoxia inducible factor-1α …

There is an urgent need for exploring new actionable targets other than androgen receptor
to improve outcome from lethal castration-resistant prostate cancer. Tumor metabolism has …

Tumor cell hypoxia is an innate environmental factor encountered during the development of
many types of human tumors, including malignant prostate tumors. For prostate cancer …